Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process
- PMID: 33934175
- PMCID: PMC8316175
- DOI: 10.1007/s00296-021-04877-5
Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process
Abstract
To establish practical recommendations for the management of patients with psoriatic arthritis (PsA) with particular clinical situations that might lead to doubts in the pharmacological decision-making. A group of six expert rheumatologists on PsA identified particular clinical situations in PsA. Then, a systematic literature review (SLR) was performed to analyse the efficacy and safety of csDMARDs, b/tsDMARDs in PsA. In a nominal group meeting, the results of the SLR were discussed and a set of recommendations were proposed for a Delphi process. A total of 65 rheumatologists were invited to participate in the Delphi. Agreement was defined if ≥ 70% of the participants voted ≥ 7 (from 1, totally disagree to 10, totally agree). For each recommendation, the level of evidence and grade of recommendation was established based on the Oxford Evidence-Based Medicine categorisation. Particular clinical situations included monoarthritis, axial disease, or non-musculoskeletal manifestations. The SLR finally comprised 131 articles. A total of 16 recommendations were generated, all but 1 reached consensus. According to them, it is crucial to carefully analyse the impact of individual manifestations on patients (disability, quality of life, etc.), but also to recognise the impact of each drug singularities on selected clinical phenotypes to adopt the most appropriate treatment strategy. Early diagnosis and treatment to target approach, along with a close risk management, is also necessary. These recommendations are intended to complement gaps in national and international guidelines by helping health professionals address and manage particular clinical situations in PsA.
Keywords: Disease-modifying antirheumatic drugs; Manifestations; Psoriatic arthritis; Recommendations; Systematic literature review.
© 2021. The Author(s).
Conflict of interest statement
All of the authors received honoraria from Pfizer for participation in this project. Francisco Rebollo and Susana Gómez work for Pfizer. Agustí Sellas has received honoraria as speaker and for consulting from Pfizer, Lilly Novartis, Janssen, Amgen. Julio Ramírez has participated at symposiums and/or advisory boards organised by Pfizer, Abbvie, MSD, UCB, Novartis, BMS, Lilly, Janssen, Amgen and Roche and his department has received research grants from Pfizer, Abbvie, Novartis and Janssen. Rubén Queiro has received honoraria as speaker, researcher and consultor from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Novartis. Rosario García-Vicuña reports personal fees from Pfizer, during the conduct of the study; grants, personal fees and non-financial support from Abbvie, grants, personal fees and non-financial support from BMS, personal fees from Biogen, personal fees from Celltrion, grants, personal fees and non-financial support from Lilly, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from MSD, personal fees and non-financial support from Pfizer, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants from Janssen, outside the submitted work. Estibaliz Loza has received research grants from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Roche, Abbvie, BMS, Novartis. Noemí Garrido has received personal fees from Pfizer, Abbie, Lilly, Gedeon Richter, Novartis, Sanofi y Janssen. The rest of authors declare no conflicts of interest.
Similar articles
-
Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert's Document Based on a Systematic Literature Review and Extended Delphi Process.Rheumatol Ther. 2023 Oct;10(5):1215-1240. doi: 10.1007/s40744-023-00575-9. Epub 2023 Jul 14. Rheumatol Ther. 2023. PMID: 37450194 Free PMC article.
-
Recommendations for the use of methotrexate in psoriatic arthritis.Reumatol Clin (Engl Ed). 2018 Jul-Aug;14(4):183-190. doi: 10.1016/j.reuma.2017.08.011. Epub 2017 Oct 17. Reumatol Clin (Engl Ed). 2018. PMID: 29050840 English, Spanish.
-
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8. Ann Rheum Dis. 2014. PMID: 23749611 Free PMC article.
-
Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA).Reumatismo. 2016 Dec 16;68(3):126-136. doi: 10.4081/reumatismo.2016.913. Reumatismo. 2016. PMID: 27981814
-
The Saudi consensus recommendations for the management of psoriatic arthritis (2023).Clin Rheumatol. 2024 Mar;43(3):879-894. doi: 10.1007/s10067-024-06867-x. Epub 2024 Jan 13. Clin Rheumatol. 2024. PMID: 38217738 Free PMC article. Review.
Cited by
-
Haemoglobin for Fall Risk Screening in Gynaecological and Obstetric Wards: Retrospective Survey and Delphi Validation.Nurs Open. 2025 Jan;12(1):e70124. doi: 10.1002/nop2.70124. Nurs Open. 2025. PMID: 39726329 Free PMC article.
-
Navigating Psoriatic Arthritis: Treatment Pathways and Patient-Specific Strategies for Improved Outcomes.Drugs. 2025 Jul;85(7):867-882. doi: 10.1007/s40265-025-02192-y. Epub 2025 May 11. Drugs. 2025. PMID: 40350472 Free PMC article. Review.
References
-
- Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewe RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159. - DOI - PMC - PubMed
-
- Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I, van der Heijde D, Baraliakos X, Falzon L, Gossec L. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2020;79(6):778–786. doi: 10.1136/annrheumdis-2020-217163. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous